Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020534 | 0.87 | SLC1A3 (0.51) | LTA4HSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL6016194 | 0.86 | ALDH1A1 (0.50) | LTA4HSYKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27750910 | 0.83 | SLC1A1 (0.58) | LTA4HSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL24689566 | 0.82 | LTA4H (0.50) | LTA4HSYKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27351866 | 0.82 | SLC1A3 (0.49) | LTA4HSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL6016841 | 0.80 | ALDH1A1 (0.50) | LTA4HSYKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27428409 | 0.80 | CTSB (0.47) | SYKKMT2AALDH1A1POLBCTSB | |
| SCHEMBL30011662 | 0.79 | SLC1A3 (0.49) | LTA4HSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL28628857 | 0.79 | POLB (0.49) | LTA4HSYKCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL27835470 | 0.79 | LTA4H (0.44) | LTA4HSYKSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2001518-B1 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2004352-B1 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7795221-B2 | Linear natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2004633-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004352-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2001518-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115164-A9 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007115182-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115175-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | LTA4H 4321/4885SYK 3462/4885SLC1A3 710/4885 |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | LTA4H 4501/4885SYK 2248/4885SLC1A3 1777/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | LTA4H 3800/4885SYK 3815/4885SLC1A3 548/4885 |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | LTA4H 4103/4885SYK 2048/4885SLC1A3 1039/4885 |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | LTA4H 4121/4885SYK 1556/4885SLC1A3 1411/4885 |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | LTA4H 4501/4885SYK 2248/4885SLC1A3 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.